Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial

BACKGROUND: Canagliflozin reduced renal and cardiovascular events in people with type 2 diabetes in the CREDENCE trial. We assessed efficacy and safety of canagliflozin by initial estimated glomerular filtration rate (eGFR). METHODS: CREDENCE randomly assigned 4401 participants with an eGFR of 30 to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Soc Nephrol
Main Authors: Jardine, Meg J., Zhou, Zien, Mahaffey, Kenneth W., Oshima, Megumi, Agarwal, Rajiv, Bakris, George, Bajaj, Harpreet S., Bull, Scott, Cannon, Christopher P., Charytan, David M., de Zeeuw, Dick, Di Tanna, Gian Luca, Greene, Tom, Heerspink, Hiddo J.L., Levin, Adeera, Neal, Bruce, Pollock, Carol, Qiu, Rose, Sun, Tao, Wheeler, David C., Zhang, Hong, Zinman, Bernard, Rosenthal, Norman, Perkovic, Vlado
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Nephrology 2020
Assuntos:
Clinical Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7217416/
https://ncbi.nlm.nih.gov/pubmed/32354987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2019111168
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados